Two Types of Magnetic Brain Stimulation Compared in Teenagers With Depression
Compares two magnetic stimulation treatments in teenagers with major depressive disorder.
Plain-language title generated from the registry record
Registry title: Comparing 10 Hz rTMS and iTBS for Adolescent Depression
Key facts
- Where
- Jinan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 11 and 19 years old?
Source: NCT07873060, who can take part
Where in China
- Shandong Mental Health CenterJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT07873060
- Record updated
- 14 October 2026
- Original description
This trial compares two transcranial magnetic stimulation (TMS) protocols-10 Hz rTMS and intermittent theta burst stimulation (iTBS)-in adolescents with major depressive disorder. Eighty participants aged 11-19 years will be randomly assigned to receive either 10 Hz rTMS or iTBS over a two-week period. Clinical symptoms, cognitive function, brain imaging, and neurophysiological measures will be assessed at baseline, immediately post-treatment, and at a 1-month follow-up to evaluate both the immediate and sustained therapeutic effects and underlying mechanisms.Read full original descriptionShow less
A Randomized Controlled Trial Protocol Comparing 10 Hz rTMS and iTBS for Adolescent Depression: Clinical Efficacy, Neurocognitive and Neurobiological Mechanisms
This trial compares two transcranial magnetic stimulation (TMS) protocols-10 Hz rTMS and intermittent theta burst stimulation (iTBS)-in adolescents with major depressive disorder. Eighty participants aged 11-19 years will be randomly assigned to receive either 10 Hz rTMS or iTBS over a two-week period. Clinical symptoms, cognitive function, brain imaging, and neurophysiological measures will be assessed at baseline, immediately post-treatment, and at a 1-month follow-up to evaluate both the immediate and sustained therapeutic effects and underlying mechanisms.
**Inclusion Criteria:**; Aged 11 to 19 years; Meeting the DSM-5 criteria for MDD; Absence of current or past psychotic symptoms (e.g., auditory or visual hallucinations); No comorbid schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, panic disorder, or other severe psychiatric conditions; No contraindications to MRI or TMS, including implanted cardiac pacemakers, neurostimulators, artificial metal heart valves, intracranial aneurysm clips, cochlear implants, or other metallic implants; **Exclusion Criteria:**; Alcohol or substance dependence; Severe or unstable medical conditions, including neurological, endocrine, and rheumatic diseases, brain disorders, traumatic brain injury or surgery, and infectious diseases; Recent receipt of rTMS or electroconvulsive therapy; High suicide risk; A history of epilepsy or unprovoked seizures; Pregnancy.